The company said total revenue for Q4 2024 rose 6% from a year earlier to $7.6 billion, and full-year revenue for 2023 increased 6% to $28.8 billion. It said higher sales in HIV, Oncology and Liver Disease were partly offset by lower Veklury sales.

1. 01

   The company said total revenue for Q4 2024 rose 6% from a year earlier to $7.6 billion, and full-year revenue for 2023 increased 6% to $28.8 billion. It said higher sales in HIV, Oncology and Liver Disease were partly offset by lower Veklury sales.

2. 02

   Gilead said its full-year 2024 diluted EPS fell to $0.38 from $4.50 in 2023, and its non-GAAP diluted EPS declined to $4.62 from $6.72. It attributed the GAAP decrease to an Immunomedics-related pre-tax IPR&D impairment charge of $4.2 billion and acquired IPR&D expenses of $3.9 billion tied to the CymaBay acquisition in Q1 2024.

3. 03

   Gilead said full-year 2024 HIV product sales rose 8% from 2023 to $19.6 billion, and Biktarvy sales grew 13% to $13.4 billion. The company said higher demand mainly drove the Biktarvy increase.

4. 04

   The company said it expects full-year 2025 product sales of $28,200 million to $28,600 million and non-GAAP diluted EPS of $7.70 to $8.10. It also said it generated $3.0 billion in operating cash flow in Q4 2024 and issued $3.5 billion of senior unsecured notes.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.